company background image
2DT logo

Amneal Pharmaceuticals DB:2DT Stock Report

Last Price

€7.95

Market Cap

€2.5b

7D

3.2%

1Y

64.9%

Updated

17 Jan, 2025

Data

Company Financials +

Amneal Pharmaceuticals, Inc.

DB:2DT Stock Report

Market Cap: €2.5b

My Notes

Capture your thoughts, links and company narrative

Amneal Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Amneal Pharmaceuticals
Historical stock prices
Current Share PriceUS$7.95
52 Week HighUS$8.55
52 Week LowUS$4.76
Beta1.1
1 Month Change5.30%
3 Month Change8.16%
1 Year Change64.94%
3 Year Change108.12%
5 Year Change75.89%
Change since IPO-56.82%

Recent News & Updates

Recent updates

Shareholder Returns

2DTDE PharmaceuticalsDE Market
7D3.2%0.7%2.6%
1Y64.9%-13.3%13.4%

Return vs Industry: 2DT exceeded the German Pharmaceuticals industry which returned -13.2% over the past year.

Return vs Market: 2DT exceeded the German Market which returned 12.1% over the past year.

Price Volatility

Is 2DT's price volatile compared to industry and market?
2DT volatility
2DT Average Weekly Movement5.8%
Pharmaceuticals Industry Average Movement5.5%
Market Average Movement4.8%
10% most volatile stocks in DE Market11.5%
10% least volatile stocks in DE Market2.4%

Stable Share Price: 2DT has not had significant price volatility in the past 3 months compared to the German market.

Volatility Over Time: 2DT's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20027,850Chirag Patelamneal.com

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.

Amneal Pharmaceuticals, Inc. Fundamentals Summary

How do Amneal Pharmaceuticals's earnings and revenue compare to its market cap?
2DT fundamental statistics
Market cap€2.51b
Earnings (TTM)-€179.49m
Revenue (TTM)€2.61b

1.0x

P/S Ratio

-13.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
2DT income statement (TTM)
RevenueUS$2.68b
Cost of RevenueUS$1.70b
Gross ProfitUS$979.05m
Other ExpensesUS$1.16b
Earnings-US$184.45m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.60
Gross Margin36.53%
Net Profit Margin-6.88%
Debt/Equity Ratio-7,524.6%

How did 2DT perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/17 07:13
End of Day Share Price 2025/01/17 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Amneal Pharmaceuticals, Inc. is covered by 20 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Balaji PrasadBarclays
Balaji PrasadBarclays
Gary NachmanBMO Capital Markets Equity Research